SG10201914067XA - Humanized anti-tau antibodies - Google Patents
Humanized anti-tau antibodiesInfo
- Publication number
- SG10201914067XA SG10201914067XA SG10201914067XA SG10201914067XA SG10201914067XA SG 10201914067X A SG10201914067X A SG 10201914067XA SG 10201914067X A SG10201914067X A SG 10201914067XA SG 10201914067X A SG10201914067X A SG 10201914067XA SG 10201914067X A SG10201914067X A SG 10201914067XA
- Authority
- SG
- Singapore
- Prior art keywords
- humanized anti
- tau antibodies
- tau
- antibodies
- humanized
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462018436P | 2014-06-27 | 2014-06-27 | |
| US201462080903P | 2014-11-17 | 2014-11-17 | |
| US201562170036P | 2015-06-02 | 2015-06-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201914067XA true SG10201914067XA (en) | 2020-03-30 |
Family
ID=54938957
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201914067XA SG10201914067XA (en) | 2014-06-27 | 2015-06-26 | Humanized anti-tau antibodies |
| SG11201610862VA SG11201610862VA (en) | 2014-06-27 | 2015-06-26 | Humanized anti-tau antibodies |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201610862VA SG11201610862VA (en) | 2014-06-27 | 2015-06-26 | Humanized anti-tau antibodies |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US9957317B2 (en) |
| EP (1) | EP3182987B1 (en) |
| JP (3) | JP6626892B2 (en) |
| KR (1) | KR102431596B1 (en) |
| CN (1) | CN106659759B (en) |
| AU (2) | AU2015279643B2 (en) |
| BR (1) | BR112016030686A2 (en) |
| CA (2) | CA3094638A1 (en) |
| CL (1) | CL2016003346A1 (en) |
| CR (1) | CR20170026A (en) |
| DO (1) | DOP2016000335A (en) |
| EC (1) | ECSP17005649A (en) |
| ES (1) | ES2959528T3 (en) |
| IL (3) | IL249734B (en) |
| MA (1) | MA40229A (en) |
| MX (2) | MX2017000205A (en) |
| MY (1) | MY184540A (en) |
| NZ (1) | NZ727919A (en) |
| PE (1) | PE20170665A1 (en) |
| PH (2) | PH12016502608A1 (en) |
| RU (1) | RU2743152C2 (en) |
| SG (2) | SG10201914067XA (en) |
| TW (3) | TW202136296A (en) |
| UA (1) | UA122771C2 (en) |
| UY (1) | UY36194A (en) |
| WO (1) | WO2015200806A2 (en) |
| ZA (1) | ZA201608875B (en) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9834596B2 (en) | 2012-07-03 | 2017-12-05 | Washington University | Antibodies to tau |
| ES2766762T3 (en) | 2013-03-13 | 2020-06-15 | Prothena Biosciences Ltd | Tau immunotherapy |
| TW202136296A (en) | 2014-06-27 | 2021-10-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | Humanized anti-tau antibodies |
| TWI827405B (en) | 2015-06-05 | 2023-12-21 | 美商建南德克公司 | Anti-tau antibodies and methods of use |
| WO2016201434A2 (en) * | 2015-06-12 | 2016-12-15 | C2N Diagnostics, Llc | Stable formulations of humanized anti-tau antibody |
| EP3445785B1 (en) | 2016-04-18 | 2022-06-22 | Faron Pharmaceuticals OY | Humanized anti clever-1 antibodies and their use |
| CN109415432B (en) * | 2016-05-02 | 2022-07-08 | 普罗塞纳生物科学有限公司 | TAU immunotherapy |
| KR20230070336A (en) | 2016-05-02 | 2023-05-22 | 프로테나 바이오사이언시즈 리미티드 | Antibodies recognizing tau |
| UA124148C2 (en) | 2016-05-02 | 2021-07-28 | Протена Біосайенсіс Лімітед | Antibodies recognizing tau |
| US10570196B2 (en) * | 2016-07-20 | 2020-02-25 | Anahit Ghochikyan | Humanized anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
| AU2017322656B2 (en) * | 2016-09-10 | 2024-02-29 | Yeda Research And Development Co. Ltd. | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| KR20190054094A (en) | 2016-09-27 | 2019-05-21 | 세로 테라퓨틱스, 인코포레이티드 | Chimeric phagocytic receptor molecule |
| KR20240035636A (en) | 2016-12-07 | 2024-03-15 | 제넨테크, 인크. | Anti-tau antibodies and methods of their use |
| JP7193457B2 (en) | 2016-12-07 | 2022-12-20 | ジェネンテック， インコーポレイテッド | Anti-TAU antibody and method of use |
| MA47499A (en) | 2017-02-17 | 2019-12-25 | Denali Therapeutics Inc | ANTI-TAU BODIES AND THEIR METHODS OF USE |
| JP2018139530A (en) | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | Humanized antibody for treating or preventing dementia and production method therefor and therapeutic agent or prophylactic agent for dementia using same |
| CN110494446A (en) | 2017-03-28 | 2019-11-22 | 基因泰克公司 | The method for treating neurodegenerative disease |
| EP3619233A4 (en) | 2017-05-02 | 2021-03-03 | Prothena Biosciences Limited | Antibodies recognizing tau |
| KR20200100598A (en) | 2017-09-26 | 2020-08-26 | 세로 테라퓨틱스, 인코포레이티드 | Chimeric phagocytosis receptor molecules and methods of use |
| GEP20227406B (en) | 2017-10-02 | 2022-08-25 | Merck Sharp & Dohme | Chromane monobactam compounds for the treatment of bacterial infections |
| SG11202003392VA (en) * | 2017-10-16 | 2020-05-28 | Eisai R&D Man Co Ltd | Anti-tau antibodies and uses thereof |
| EP3768706A1 (en) * | 2018-03-23 | 2021-01-27 | AbbVie Deutschland GmbH & Co. KG | Stable aqueous anti-tau antibody formulations |
| WO2019191332A1 (en) | 2018-03-28 | 2019-10-03 | Cero Therapeutics, Inc. | Chimeric engulfment receptors and uses thereof for neurodegenerative diseases |
| CA3107933A1 (en) * | 2018-08-01 | 2020-02-06 | Imcheck Therapeutics Sas | Anti-btn3a antibodies and their use in treating cancer or infectious disorders |
| CA3131531A1 (en) | 2019-03-03 | 2020-09-10 | Prothena Biosciences Limited | Antibodies recognizing tau |
| CN114430744A (en) * | 2019-07-15 | 2022-05-03 | 阿德尔公司 | anti-Tau antibodies and uses thereof |
| CA3148740A1 (en) | 2019-08-06 | 2021-02-11 | Aprinoia Therapeutics Limited | Antibodies that bind to pathological tau species and uses thereof |
| EP4171633A1 (en) | 2020-06-25 | 2023-05-03 | Merck Sharp & Dohme LLC | High affinity antibodies targeting tau phosphorylated at serine 413 |
| KR20240049296A (en) | 2021-08-27 | 2024-04-16 | 제넨테크, 인크. | How to Treat Tauopathy |
| WO2023041805A1 (en) | 2021-09-20 | 2023-03-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor |
| WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2023178049A1 (en) | 2022-03-14 | 2023-09-21 | Genentech, Inc. | Predicting neurodegenerative diseases based on speech analyses |
| WO2023250326A1 (en) | 2022-06-21 | 2023-12-28 | Genentech, Inc. | Detecting longitudinal progression of alzheimer's disease (ad) based on speech analyses |
| CN115724970B (en) * | 2022-07-27 | 2023-10-20 | 生工生物工程（上海）股份有限公司 | Binding protein capable of specifically binding E-CAD polypeptide and application thereof |
| CN116375857A (en) * | 2023-03-30 | 2023-07-04 | 天津鸿宇泰生物科技有限公司 | Single-chain antibody for detecting Tau protein, and preparation method and application thereof |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI884505A (en) | 1987-10-02 | 1989-04-03 | Du Pont | IMMUNOANALYS, I VILKEN ANVAENDS IGG-UPPSNAPPANDE ANTIKROPPAR OCH DETEKTERINGSSYSTEM FOER FLERA MONOCLONALA ANTIKROPPAR. |
| EP0600951A4 (en) | 1991-08-01 | 1996-10-30 | Paul H Voorheis | Diagnostic method for alzheimer's disease. |
| US5733734A (en) | 1991-08-14 | 1998-03-31 | The Trustees Of The University Of Pennsylvania | Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments |
| JP3909084B2 (en) | 1991-10-25 | 2007-04-25 | エヌ・ブイ・インノジェネティクス・ソシエテ・アノニム | Monoclonal antibody against microtubule-associated protein tau |
| US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
| US7408027B1 (en) | 1991-12-06 | 2008-08-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften | Tools for the diagnosis and treatment of Alzheimer's disease |
| DE69230148T2 (en) | 1991-12-06 | 2000-05-04 | Max Planck Gesellschaft | Tools for the diagnosis and treatment of Alzheimer's disease. |
| JPH06239899A (en) | 1993-02-12 | 1994-08-30 | Teijin Ltd | Antibody for human tau protein and determination of human tau protein in body fluid utilizing the same |
| JPH10506381A (en) | 1994-07-29 | 1998-06-23 | イノジェネティックス・ナムローゼ・フェンノートシャップ | Monoclonal antibodies specific for a particular subclass or form of phosphorylated TAU epitopes, hybridomas secreting them, antigen recognition of these antibodies and their applications |
| WO1997034145A1 (en) | 1996-03-13 | 1997-09-18 | Mitsubishi Chemical Corporation | Antiphosphorylated tau protein antibody and method for detecting alzheimer's disease with the use of the same |
| WO1998022120A1 (en) | 1996-11-19 | 1998-05-28 | The Wistar Institute Of Anatomy & Biology | Diagnostic and therapeutic reagents for alzheimer's disease |
| US6797478B1 (en) | 1998-03-05 | 2004-09-28 | University Of Cincinnati | Method of detecting axonal damage, from associated disease states using tau monoclonal antibodies |
| BR9913112A (en) | 1998-09-08 | 2001-05-08 | Innogenetics Nv | Tau as a marker for initial damage from cns |
| US6972125B2 (en) * | 1999-02-12 | 2005-12-06 | Genetics Institute, Llc | Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith |
| US6589746B1 (en) | 1999-10-21 | 2003-07-08 | University Of Cincinnati | Method of detecting axonally-derived protein tau in patients with traumatic CNS injury |
| JP4582874B2 (en) | 2000-07-13 | 2010-11-17 | 富士通株式会社 | Polarization mode dispersion compensation method and polarization mode dispersion compensation apparatus |
| AT500379B8 (en) * | 2001-02-02 | 2009-08-15 | Axon Neuroscience | TAU PROTEINS |
| AR035119A1 (en) | 2001-08-16 | 2004-04-14 | Lilly Co Eli | ANTI-HTNFSF13B HUMAN ANTI-BODIES |
| WO2003057881A1 (en) | 2001-12-28 | 2003-07-17 | Chugai Seiyaku Kabushiki Kaisha | Method of stabilizing protein |
| GB0210121D0 (en) | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
| LT1507556T (en) | 2002-05-02 | 2016-10-10 | Wyeth Holdings Llc | Calicheamicin derivative-carrier conjugates |
| DE60323231D1 (en) | 2002-07-12 | 2008-10-09 | Axon Neuroscience | SHORTEN TAU PROTEINS |
| EP1535930B1 (en) | 2002-08-14 | 2010-10-06 | Mitsubishi Chemical Medience Corporation | Antibody specific to central nervous system tau protein |
| FI20030652A0 (en) | 2003-04-30 | 2003-04-30 | Susann Eriksson | Improved immune determination |
| NZ545776A (en) | 2003-08-22 | 2009-05-31 | Biogen Idec Inc | Improved antibodies having altered effector function and methods for making the same |
| WO2005073375A1 (en) * | 2004-01-30 | 2005-08-11 | Maxygen Holdings Ltd. | Regulated stop codon readthrough |
| US7238788B2 (en) | 2004-02-18 | 2007-07-03 | University Of Iowa Foundation | Antibodies to phosphorylated tau, methods of making and methods of use |
| KR20100036324A (en) | 2005-02-19 | 2010-04-07 | 주식회사 피플바이오 | Method for differentially detecting multimeric form from monomeric form of multimer-forming polypeptides |
| EP1940442A4 (en) | 2005-08-04 | 2009-08-19 | Einstein Coll Med | Phosphorylation of tau by abl |
| ES2321996B1 (en) | 2006-01-26 | 2010-03-05 | Consejo Superior Investig. Cientificas | USE OF COMPOUNDS THAT JOIN THE DOMAIN OF UNION TO TAU MICROTUBLES IN THE DEVELOPMENT OF PHARMACEUTICAL COMPOSITIONS, SUCH PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATION IN THE TREATMENT OF TAUOPATIAS. |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| ME00581B (en) * | 2006-07-18 | 2011-12-20 | Sanofi Aventis | Antagonist antibody against epha2 for the treatment of cancer |
| WO2008140639A2 (en) | 2007-02-08 | 2008-11-20 | Oligomerix, Inc. | Biomarkers and assays for alzheimer's disease |
| NZ588555A (en) | 2008-04-24 | 2012-06-29 | Bristol Myers Squibb Co | Use of epothilone d in treating tau-associated diseases including alzheimer's disease |
| CN101307108B (en) | 2008-06-25 | 2012-04-04 | 南京川博生物技术有限公司 | Anti-phosphorylation Tau protein antibody use for detecting AD sign abnormal phosphation Tau protein level |
| WO2010036959A2 (en) * | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| WO2010096751A1 (en) | 2009-02-23 | 2010-08-26 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating a disease mediated by soluble oligomeric amyloid beta |
| US9605054B2 (en) | 2009-02-23 | 2017-03-28 | The Board Of Trustees Of The University Of Illinois | Composition and method for treating a tauopathy |
| UA107571C2 (en) | 2009-04-03 | 2015-01-26 | PHARMACEUTICAL COMPOSITION | |
| WO2010129674A2 (en) | 2009-05-05 | 2010-11-11 | New York University | Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins |
| US8609097B2 (en) * | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| EP2440234A4 (en) | 2009-06-10 | 2013-11-06 | Univ New York | Immunological targeting of pathological tau proteins |
| JP5370780B2 (en) | 2009-06-17 | 2013-12-18 | 株式会社フジクラ | Multi-clad optical fiber, optical fiber module, fiber laser and fiber amplifier |
| IN2012DN00446A (en) | 2009-07-30 | 2015-05-15 | Pfizer Vaccines Llc | |
| WO2011026031A1 (en) | 2009-08-28 | 2011-03-03 | The Board Of Regents Of The University Of Texas System | Antibodies that bind tau oligomers |
| US8648044B2 (en) | 2009-09-24 | 2014-02-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | FKBP52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction |
| WO2011109112A2 (en) | 2010-03-05 | 2011-09-09 | Albert Einstein College Of Medicine Of Yeshiva University | Method of detecting tau protein and tau fragments in serum |
| WO2011127324A2 (en) * | 2010-04-08 | 2011-10-13 | JN Biosciences, LLC | Antibodies to cd122 |
| AU2013205313B2 (en) | 2010-10-07 | 2016-05-19 | Ac Immune S.A. | Phosphospecific antibodies recognising tau |
| EP2987807A3 (en) | 2010-10-07 | 2016-06-01 | AC Immune S.A. | Antibodies recognising phospho-tau |
| LT2627672T (en) * | 2010-10-11 | 2018-12-10 | Biogen International Neuroscience Gmbh | Human anti-tau antibodies |
| US8703137B2 (en) | 2011-01-31 | 2014-04-22 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| US8697076B2 (en) | 2011-04-27 | 2014-04-15 | Northwestern University | Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies |
| US20120321594A1 (en) | 2011-05-06 | 2012-12-20 | New York University | Methods of controlling axon or dendrite development of neuronal cells |
| EP2709728B1 (en) | 2011-05-20 | 2019-01-23 | Oligomerix, Inc. | Tau protease methods of use |
| GB201111361D0 (en) | 2011-07-04 | 2011-08-17 | Nordic Bioscience As | Biochemical markers for neurodegenerative conditions |
| GB201112056D0 (en) | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
| WO2013012811A2 (en) | 2011-07-19 | 2013-01-24 | New York University | Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides |
| ES2656442T3 (en) | 2011-09-19 | 2018-02-27 | Axon Neuroscience Se | Protein-based therapy and diagnosis of a tau-mediated pathology in Alzheimer's disease |
| JP6358953B2 (en) | 2011-10-07 | 2018-07-18 | エーシー イミューン エス．エー． | Phospho-specific antibody that recognizes tau |
| WO2013063086A1 (en) | 2011-10-24 | 2013-05-02 | Intellect Neurosciences, Inc. | Compositions and methods for treatment of proteinopathies |
| BR112014009962A2 (en) * | 2011-10-27 | 2019-09-24 | Nkt Therapeutics Inc | humanized inkt antibodies |
| HUE045656T2 (en) | 2011-12-20 | 2020-01-28 | Janssen Biotech Inc | Anti-phf-tau antibodies and their uses |
| US20130251731A1 (en) * | 2012-03-22 | 2013-09-26 | The Trustees Of The University Of Pennsylvania | Tau Acetylation in the Pathogenesis of Alzheimers Disease and Other Related Tauopathies |
| EP2834270B1 (en) | 2012-04-05 | 2019-10-30 | AC Immune S.A. | Humanized tau antibody |
| WO2013177104A2 (en) | 2012-05-21 | 2013-11-28 | Felder Mitchell S | Treatment for tauopathies |
| PT2857039T (en) * | 2012-05-31 | 2020-01-07 | Teijin Pharma Ltd | Therapeutic agent or prophylactic agent for dementia |
| US9834596B2 (en) * | 2012-07-03 | 2017-12-05 | Washington University | Antibodies to tau |
| BR112015003326A2 (en) * | 2012-08-16 | 2017-07-04 | Ipierian Inc | methods of treatment of a tauopathy |
| US20140056901A1 (en) | 2012-08-21 | 2014-02-27 | The Institute For Molecular Medicine | Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
| WO2014031697A2 (en) | 2012-08-21 | 2014-02-27 | The Institute Of Molecular Medicine | COMPOSITIONS AND METHODS RELATED TO DISEASES ASSOCIATED WITH DEPOSITS OF AMYLOID, TAU, AND α-SYNUCLEIN |
| CA2887933A1 (en) | 2012-10-12 | 2014-04-17 | Arizona Board Of Agents, On Behalf Of Arizona State University | Antibody based reagents that specifically recognize toxic oligomeric forms of tau |
| WO2014089104A1 (en) * | 2012-12-03 | 2014-06-12 | Washington University | Method for detection of aggregates in biological samples |
| US8921150B2 (en) | 2012-12-06 | 2014-12-30 | Taiwan Semiconductor Manufacturing Co., Ltd. | Process to achieve contact protrusion for single damascene via |
| US9200068B2 (en) | 2012-12-18 | 2015-12-01 | Regents Of The University Of Minnesota | Compositions and methods related to tauopathy |
| AU2013361107B2 (en) | 2012-12-21 | 2018-08-23 | Biogen International Neuroscience Gmbh | Human anti-tau antibodies |
| WO2014096321A1 (en) | 2012-12-21 | 2014-06-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies specific to tau phosphorylated at serine 422 and uses for the treatment and diagnosis of tauopathies |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| ES2766762T3 (en) | 2013-03-13 | 2020-06-15 | Prothena Biosciences Ltd | Tau immunotherapy |
| WO2014159244A2 (en) | 2013-03-14 | 2014-10-02 | Merck Patent Gmbh | O-GlcNAc TAU ANTIBODY AND USE THEREOF |
| EP2968548B1 (en) | 2013-03-15 | 2020-09-09 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
| MX2015012872A (en) | 2013-03-15 | 2016-02-03 | Ac Immune Sa | Anti-tau antibodies and methods of use. |
| TW202136296A (en) | 2014-06-27 | 2021-10-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | Humanized anti-tau antibodies |
-
2015
- 2015-06-25 TW TW109146224A patent/TW202136296A/en unknown
- 2015-06-25 TW TW108111964A patent/TWI734975B/en active
- 2015-06-25 TW TW104120634A patent/TWI664190B/en not_active IP Right Cessation
- 2015-06-26 MY MYPI2016704772A patent/MY184540A/en unknown
- 2015-06-26 PE PE2016002780A patent/PE20170665A1/en unknown
- 2015-06-26 KR KR1020167036625A patent/KR102431596B1/en active IP Right Grant
- 2015-06-26 ES ES15810923T patent/ES2959528T3/en active Active
- 2015-06-26 AU AU2015279643A patent/AU2015279643B2/en active Active
- 2015-06-26 MX MX2017000205A patent/MX2017000205A/en unknown
- 2015-06-26 SG SG10201914067XA patent/SG10201914067XA/en unknown
- 2015-06-26 CN CN201580046263.9A patent/CN106659759B/en active Active
- 2015-06-26 NZ NZ727919A patent/NZ727919A/en not_active IP Right Cessation
- 2015-06-26 SG SG11201610862VA patent/SG11201610862VA/en unknown
- 2015-06-26 CR CR20170026A patent/CR20170026A/en unknown
- 2015-06-26 UY UY0001036194A patent/UY36194A/en not_active Application Discontinuation
- 2015-06-26 CA CA3094638A patent/CA3094638A1/en not_active Abandoned
- 2015-06-26 EP EP15810923.1A patent/EP3182987B1/en active Active
- 2015-06-26 CA CA2953809A patent/CA2953809C/en active Active
- 2015-06-26 BR BR112016030686A patent/BR112016030686A2/en not_active Application Discontinuation
- 2015-06-26 WO PCT/US2015/038002 patent/WO2015200806A2/en active Application Filing
- 2015-06-26 JP JP2017520755A patent/JP6626892B2/en active Active
- 2015-06-26 UA UAA201700707A patent/UA122771C2/en unknown
- 2015-06-26 RU RU2017102514A patent/RU2743152C2/en active
- 2015-06-26 MA MA040229A patent/MA40229A/en unknown
-
2016
- 2016-09-06 US US15/257,086 patent/US9957317B2/en active Active
- 2016-12-22 IL IL249734A patent/IL249734B/en active IP Right Grant
- 2016-12-22 ZA ZA2016/08875A patent/ZA201608875B/en unknown
- 2016-12-23 PH PH12016502608A patent/PH12016502608A1/en unknown
- 2016-12-26 DO DO2016000335A patent/DOP2016000335A/en unknown
- 2016-12-27 CL CL2016003346A patent/CL2016003346A1/en unknown
-
2017
- 2017-01-04 MX MX2021008888A patent/MX2021008888A/en unknown
- 2017-01-27 EC ECIEPI20175649A patent/ECSP17005649A/en unknown
-
2018
- 2018-03-23 US US15/934,413 patent/US20180371066A1/en not_active Abandoned
-
2019
- 2019-12-02 JP JP2019217837A patent/JP2020054356A/en active Pending
-
2020
- 2020-03-27 IL IL273656A patent/IL273656B/en unknown
-
2021
- 2021-01-04 PH PH12021550023A patent/PH12021550023A1/en unknown
- 2021-07-08 AU AU2021204800A patent/AU2021204800A1/en active Pending
- 2021-12-02 JP JP2021195942A patent/JP2022050392A/en active Pending
- 2021-12-02 IL IL288649A patent/IL288649A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288649A (en) | Humanized anti-tau antibodies | |
| ZA201803874B (en) | Humanized anti-cd73 antibodies | |
| IL250583A0 (en) | Anti-tigit antibodies | |
| SG11201703403TA (en) | Anti-tim-3 antibodies | |
| SG11201703346PA (en) | Anti-tim-3 antibodies | |
| HK1258375A1 (en) | Humanized anti-cll-1 antibodies | |
| IL256579A (en) | Humanized antibodies | |
| IL252422A0 (en) | Effector-deficient anti-cd32a antibodies | |
| PT3101131T (en) | Anti-transthyretin humanized antibody | |
| IL262776A (en) | Humanized anti-il-1r3 antibodies | |
| IL250374B (en) | Anti-ceramide antibodies | |
| EP3131581A4 (en) | Humanized anti-tf-antigen antibodies | |
| IL246603B (en) | Novel anti-netrin-1 antibody | |
| PL3371216T3 (en) | Humanized anti-bag3 antibodies | |
| IL247988A0 (en) | Antibodies against hpa-1a | |
| GB201419092D0 (en) | Anti-TIM-3 antibodies | |
| GB201419089D0 (en) | Anti-TIM-3 antibodies | |
| GB201417614D0 (en) | Antibodies | |
| GB201414270D0 (en) | Antibodies | |
| GB201405775D0 (en) | Antibodies | |
| GB201401200D0 (en) | Antibodies |